BioXcel Therapeutics EVP & Chief Commercial Officer William P. Kane resigns effective immediately

BioXcel Therapeutics, Inc.

William P. Kane, Jr., EVP and Chief Commercial Officer, resigned on October 8, 2021, effective immediately.
No reason for the resignation was provided in the filing.
No successor or interim appointment has been announced.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

William P. Kane, Jr.

Executive Vice President and Chief Commercial Officer

BTAI · BioXcel Therapeutics, Inc.

Effective: 2021-10-08
Filed: October 13, 2021, 7:59 PM ET

On October 8, 2021, William P. Kane, Jr., Executive Vice President and Chief Commercial Officer of BioXcel Therapeutics, Inc. (the “Company”) tendered his resignation notice to the Company, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

William P. Kane, Jr. resigned as Executive Vice President and Chief Commercial Officer at BioXcel Therapeutics, Inc..

Action: resigned
Role: Executive Vice President and Chief Commercial Officer

Exact text from the filing

On October 8, 2021, William P. Kane, Jr., Executive Vice President and Chief Commercial Officer of BioXcel Therapeutics, Inc. (the “Company”) tendered his resignation notice to the Company, effective immediately.

View on SEC.gov

BioXcel Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-21-125849

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.